Table 1.
Characteristics of the included studies
| Study | Year | Follow-up years | Samples P/C | Age, years P/C | Male, % P/C | HTN, % P/C | Smoke, % P/C | Dsl, % P/C | Stent type | Study design | Coronary lesion |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kapur et al. [21] | 2010 | 1 | 172/178 | 64.3/63.6 | 70.7/77.9 | 20.8/18.7 | 24.6/23.2 | NA | DES | RCT | MVD (2- or 3-vessel disease) |
| Luo et al. [24] | 2012 | 3 | 99/127 | 65/66 | 70/98 | 72/87 | 43.0/54.0 | 15.0/31.0 | DES | OS | Unprotected LM disease (and/or 1-, 2-, or 3-vessel coronary disease) |
| Farkouh et al. [5] | 2012 | 1 | 953/947 | 63.2/63.1 | 73.2/69.5 | NA | 14.8/16.6 | NA | SES or PES | RCT | MVD with stenosis of more than 70% in 2 or more major epicardial vessels |
| Kamalesh et al. [8] | 2013 | 2 | 101/97 | 62.7/62.1 | 99.0/99.0 | 96.0/95.7 | 27.7/20.6 | NA | DES | RCT | MVD (2- or 3-vessel disease) |
| Kappetein et al. [9] | 2013 | 5 | 231/221 | NA | NA | NA | NA | NA | PES | RCT | LM and/or 3-vessel disease |
| Ben-Gal et al. [23] | 2015 | 1 | 1349/423 | 65.0/65.0 | 73.0/66.3 | 79.4/85.9 | 21.0/24.0 | 61.8/72.7 | DES | RCT | LM and/or 2-, 3-vessel disease |
| Bangalore et al. [25, 34] | 2015 | 4 | 773/773 | 64.9/64.7 | 68.0/68.0 | NA | NA | NA | EES | OS | MVD (2-, 3-vessel disease and without LM) |
| Marui et al. [26] | 2015 | 5 | 1065/933 | 68.7/67.8 | 68.0/73.0 | 88.0/84.0 | 25.0/25.0 | NA | DES | OS | LM and/or 3-vessel disease |
| Ahn et al. [22] | 2015 | 5 | 102/90 | NA | NA | NA | NA | NA | SES | RCT | Unprotected LM disease with stenosis of more than 50% |
| Naito et al. [27] | 2015 | 3.8 | 256/227 | 72.7/72.7 | 78.1/68.3 | 77.0/74.0 | 58.6/62.6 | 76.6/68.7 | DES | OS | LM and/or 2-, 3-vessel disease |
| Yu et al. [28] | 2015 | 7.1 | 143/131 | 65.0/66.0 | 72.0/77.9 | 68.5/65.6 | 49.7/45.8 | 53.8/37.4 | DES | OS | Unprotected LM and 1-, 2-, or 3-vessel coronary disease |
| Zheng et al. [29] | 2016 | 3 | 348/806 | NA | NA | NA | NA | NA | DES | OS | LM and/or 1-, 2-, 3-vessel disease |
| Li et al. [30] | 2017 | 10 | 406/406 | 41.9/42.0 | 366/369 | 60.8/63.5 | 66.0/65.3 | NA | DES | OS | LM and/or 1-, 2-, 3-vessel disease |
| Ramanathan et al. [11] | 2017 | 5 | 2710/1865 | 67.3/65.2 | 72.0/73.2 | 88.1/91.8 | NA | 77.5/79.5 | DES | OS | MVD with stenosis of more than 70% in 2 or more major epicardial vessels |
| Nagendran et al. [31] | 2018 | 5 | 869/869 | 65.1/65.1 | 23.0/21.0 | 83.0/85.0 | 18.0/20.0 | 80.0/82.0 | DES | OS | LM and/or 2-, 3-vessel disease |
| Milojevic et al. [14] | 2019 | 3 | 286/268 | NA | NA | NA | NA | NA | EES | RCT | LM and/or 1-, 2-, or 3-vessel coronary disease |
HTN hypertension, Dsl dyslipidemia, P/C percutaneous coronary intervention versus coronary artery bypass surgery, DES drug-eluting stents, but type of the stents is not available, SES sirolimus-eluting stent, PES paclitaxel-eluting stent, EES everolimus-eluting stent, MVD multivessel disease, LM left main, RCT randomized controlled trials, OS observational studies, NA not available